<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03516981</url>
  </required_header>
  <id_info>
    <org_study_id>3475-495</org_study_id>
    <secondary_id>MK-3475-495</secondary_id>
    <secondary_id>194621</secondary_id>
    <secondary_id>KEYNOTE-495</secondary_id>
    <nct_id>NCT03516981</nct_id>
  </id_info>
  <brief_title>A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)</brief_title>
  <official_title>A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the utility of biomarker-based triage for study participants with
      advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study
      participants within groups defined by a biomarker-based classifier (gene expression profile
      [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in
      combination with MK-1308, MK-4280, or lenvatinib. The primary hypotheses are as follows: In
      participants receiving pembrolizumab in combination with either MK-1308, MK-4280, or
      lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants
      with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB,
      3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45%
      among participants with high GEP and high TMB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After Amendment 5, participants can receive 800 mg of MK-4280 every 3 weeks (Q3W)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to ~2 years</time_frame>
    <description>ORR was defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by local site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) per RECIST 1.1</measure>
    <time_frame>Up to ~2 years</time_frame>
    <description>PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 as assessed by local site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to ~2 years</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to ~2 years</time_frame>
    <description>An AE is any untoward medical occurrence in participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants in each treatment arm experiencing an AE will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Discontinuing Study Drug Due to AEs</measure>
    <time_frame>Up to ~2 years</time_frame>
    <description>An AE is any untoward medical occurrence in participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants in each treatment arm that discontinued study drug due to an AE will be reported.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Advanced Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>GEP low TMB low: Pembrolizumab + MK-1308</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg Q3W plus MK-1308 at the Recommended Phase 2 Dose ([RP2D], dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEP low TMB low: Pembrolizumab + MK-4280</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEP low TMB low: Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEP low TMB hi: Pembrolizumab + MK-1308</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg Q3W plus MK-1308 at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEP low TMB hi: Pembrolizumab + MK-4280</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEP low TMB hi: Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEP hi TMB low: Pembrolizumab + MK-1308</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg Q3W plus MK-1308 at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEP hi TMB low: Pembrolizumab + MK-4280</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEP hi TMB low: Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEP hi TMB hi: Pembrolizumab + MK-1308</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg Q3W plus MK-1308 at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEP hi TMB hi: Pembrolizumab + MK-4280</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEP hi TMB hi: Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W</description>
    <arm_group_label>GEP hi TMB hi: Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_label>GEP hi TMB hi: Pembrolizumab + MK-1308</arm_group_label>
    <arm_group_label>GEP hi TMB hi: Pembrolizumab + MK-4280</arm_group_label>
    <arm_group_label>GEP hi TMB low: Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_label>GEP hi TMB low: Pembrolizumab + MK-1308</arm_group_label>
    <arm_group_label>GEP hi TMB low: Pembrolizumab + MK-4280</arm_group_label>
    <arm_group_label>GEP low TMB hi: Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_label>GEP low TMB hi: Pembrolizumab + MK-1308</arm_group_label>
    <arm_group_label>GEP low TMB hi: Pembrolizumab + MK-4280</arm_group_label>
    <arm_group_label>GEP low TMB low: Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_label>GEP low TMB low: Pembrolizumab + MK-1308</arm_group_label>
    <arm_group_label>GEP low TMB low: Pembrolizumab + MK-4280</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-4280</intervention_name>
    <description>200 mg or 800 mg MK-4280 solution for IV infusion administered Q3W</description>
    <arm_group_label>GEP hi TMB hi: Pembrolizumab + MK-4280</arm_group_label>
    <arm_group_label>GEP hi TMB low: Pembrolizumab + MK-4280</arm_group_label>
    <arm_group_label>GEP low TMB hi: Pembrolizumab + MK-4280</arm_group_label>
    <arm_group_label>GEP low TMB low: Pembrolizumab + MK-4280</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>20 mg lenvatinib capsules administered orally once daily</description>
    <arm_group_label>GEP hi TMB hi: Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_label>GEP hi TMB low: Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_label>GEP low TMB hi: Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_label>GEP low TMB low: Pembrolizumab + Lenvatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-1308</intervention_name>
    <description>MK-1308 solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)</description>
    <arm_group_label>GEP hi TMB hi: Pembrolizumab + MK-1308</arm_group_label>
    <arm_group_label>GEP hi TMB low: Pembrolizumab + MK-1308</arm_group_label>
    <arm_group_label>GEP low TMB hi: Pembrolizumab + MK-1308</arm_group_label>
    <arm_group_label>GEP low TMB low: Pembrolizumab + MK-1308</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a histologically- or cytologically-confirmed diagnosis of Stage IV (American Joint
             Committee on Cancer [AJCC] v 8) NSCLC and has not had prior systemic therapy for
             advanced disease

          -  Has confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma
             kinase- (ALK-), c-ros oncogene 1- (ROS1-), or B isoform of rapidly accelerated
             fibrosarcoma- (B-Raf-) directed therapy is not indicated as primary therapy
             (documentation of absence of tumor activating EGFR mutations, B-Raf mutations, ALK
             gene rearrangements, and ROS1 gene rearrangements)

          -  Has measurable disease per RECIST 1.1 as assessed by the local site
             investigator/radiology

          -  Male participants must agree to use contraception during the treatment period and for
             ≥120 days, after the last dose of study treatment and refrain from donating sperm
             during this period. Male participants with pregnant partners must agree to use a
             condom

          -  Female participants eligible to participate if not pregnant, not breastfeeding, and
             not a woman of childbearing potential (WOCBP) or is a WOCBP who agrees to follow
             contraceptive guidance during the treatment period and for ≥120 days after the last
             dose of study treatment

          -  Provided archival tumor tissue sample or newly obtained core or excisional biopsy of a
             tumor lesion not previously irradiated

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          -  Has adequate organ function

        Exclusion Criteria:

          -  Has significant cardiovascular impairment within 12 months of the first dose of study
             drug: history of congestive heart failure greater than New York Heart Association
             (NYHA) Class II, unstable angina, myocardial infarction or cerebrovascular accident
             (CVA) stroke, or cardiac arrhythmia associated with hemodynamic instability,
             significant cardiovascular impairment, or a left ventricular ejection fraction (LVEF)
             below the institutional normal range as determined by multigated acquisition scan
             (MUGA) or echocardiogram

          -  Prolongation of QTc interval to &gt;480 milliseconds (ms)

          -  Has symptomatic ascites or pleural effusion

          -  Has had an allogenic tissue/solid organ transplant

          -  WOCBP who has a positive urine pregnancy test within 24 hours before the first dose of
             study treatment

          -  Has not recovered adequately from any toxicity and/or complications from major surgery
             prior to starting therapy, or has had major surgery within 3 weeks prior to first dose
             of study intervention

          -  Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula,
             gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition
             that might affect the absorption of lenvatinib

          -  Radiographic evidence of major blood vessel invasion/infiltration

          -  Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first
             dose of study drug

          -  Has received prior systemic chemotherapy treatment for metastatic/recurrent NSCLC

          -  Has current NSCLC disease that can be treated with curative intent with surgical
             resection, localized radiotherapy, or chemoradiation

          -  Is expected to require any other form of systemic or localized antineoplastic therapy
             while on study (including maintenance therapy with another agent for NSCLC, radiation
             therapy, and/or surgical resection)

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with
             an agent directed to another stimulatory or co-inhibitory T cell receptor

          -  Has received previous treatment with another agent targeting the Lymphocyte-activation
             gene 3 (LAG-3) receptor

          -  Has received previous treatment with another agent targeting vascular endothelial
             growth factor (VEGF) or the VEGF receptor

          -  Has received prior anticancer therapy including investigational agents within 4 weeks
             prior to randomization

          -  Has received prior radiotherapy within 2 weeks of start of study treatment or received
             lung radiation therapy of &gt;30 Gy within 6 months prior to the first dose of study
             intervention

          -  Has received a live vaccine within 30 days prior to the first dose of study treatment

          -  Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study treatment.

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior the first dose of study treatment

          -  Has a known additional malignancy that is progressing or has required active treatment
             within the past 3 years

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis

          -  Has severe hypersensitivity (≥Grade 3) to pembrolizumab, MK-4280, or lenvatinib and/or
             any of its excipients

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years
             (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive
             drugs)

          -  Has a history of (noninfectious) pneumonitis that required steroids or has current
             pneumonitis

          -  Has an active infection requiring systemic therapy

          -  Has a known history of human immunodeficiency virus (HIV) infection

          -  Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg]
             reactive) or known active hepatitis C virus (defined as HCV RNA [qualitative] is
             detected) infection

          -  Has a known history of active tuberculosis (TB; Bacillus tuberculosis)

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the study, interfere with the participant's
             participation for the full duration of the study, or is not in the best interest of
             the participant to participate, in the opinion of the treating investigator

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperating with the requirements of the study

          -  Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through 120 days
             (females and males) after the last dose of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC- HAL ( Site 8001)</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6685</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center ( Site 0137)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>916-374-3772</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco ( Site 0111)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-514-6241</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology -Santa Monica ( Site 0108)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-794-6500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine ( Site 0100)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>203-737-2587</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida ( Site 0115)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>904-953-2795</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland ( Site 0136)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-328-8611</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester - St. Mary's Hospital ( Site 0117)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>507-538-1665</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center ( Site 0112)</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>551-996-5900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center ( Site 0113)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-574-3798</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care ( Site 8005)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania ( Site 0132)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-220-9703</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center/Hillman Cancer Center ( Site 0104)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>412-864-7820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Memorial City ( Site 8006)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Tyler ( Site 8003)</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6416</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emily Couric Clinical Cancer Center ( Site 0134)</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>434-297-7784</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C. ( Site 8000)</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin- Madison Carbone Cancer Center ( Site 0130)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>608-265-3918</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital Western Sydney Local Health District ( Site 0200)</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61298818421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greenslopes Private Hospital ( Site 0202)</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61731762669</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital ( Site 0201)</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61861522222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital ( Site 0306)</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>613737770070175</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Science Centre ( Site 0304)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>41648050007955</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre ( Site 0309)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4169464501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS du Saguenay-Lac-St-Jean ( Site 0305)</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4185411234</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital ( Site 0307)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514340822223674</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital ( Site 1801)</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+85235051042</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital ( Site 1800)</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+852225553111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St James Hospital ( Site 2200)</name>
      <address>
        <city>Dublin</city>
        <zip>D08 K0Y5</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35314103756</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid Western Cancer Centre ( Site 2201)</name>
      <address>
        <city>Limerick</city>
        <zip>V94 F858</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35361482013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0702)</name>
      <address>
        <city>Meldola</city>
        <state>Forli-Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390543739100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas Research Hospital ( Site 0700)</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390282244080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU San Luigi Gonzaga di Orbassano ( Site 0707)</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390119026322</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AULSS21 Regione Veneto Ospedale Mater Salutis - Legnago ( Site 0701)</name>
      <address>
        <city>Legnago</city>
        <state>Verona</state>
        <zip>37045</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390442632418</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papardo ( Site 0706)</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390903996138</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seconda Universita degli Studi di Napoli ( Site 0704)</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390815666760</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli ( Site 0703)</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390630154953</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese ( Site 0705)</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390577586335</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital ( Site 2001)</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81335422511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR ( Site 2000)</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81335200111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 0803)</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82317877003</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 0800)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220722995</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 0802)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 0801)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82230103214</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 0805)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82234103438</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dolnoslaskie Centrum Onkologii. ( Site 0993)</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>53-413</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48713267900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0910)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48225463066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MED-POLONIA Sp. z o.o. ( Site 0907)</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48616561700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1003)</name>
      <address>
        <city>Ufa</city>
        <state>Baskortostan, Respublika</state>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Loginov Moscow Clinical Scientific Center ( Site 1008)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74953043039</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>N.N. Blokhin NMRCO ( Site 1000)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79032934813</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omsk Clinical Oncology Dispensary ( Site 1009)</name>
      <address>
        <city>Omsk</city>
        <state>Omskaya Oblast'</state>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+73812601812</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SBHI Leningrad Regional Clinical Hospital ( Site 1001)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78125922529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Petersburg City Clinical Oncology Dispensary ( Site 1002)</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78127569923</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1005)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79033434202</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National University Hospital ( Site 1901)</name>
      <address>
        <city>Singapore</city>
        <state>Central Singapore</state>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6567727839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore ( Site 1900)</name>
      <address>
        <city>Singapore</city>
        <state>Central Singapore</state>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6564368000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MPOC ( Site 2310)</name>
      <address>
        <city>Groenkloof Pretoria</city>
        <state>Gauteng</state>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27123466701</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sandton Oncology Medical Group PTY LTD ( Site 2316)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27118830900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research ( Site 2313)</name>
      <address>
        <city>Parktown-Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27113390638</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ. Pretoria and Steve Biko Academic Hospitals ( Site 2315)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27123541054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vaal Triangle Oncology Centre ( Site 2314)</name>
      <address>
        <city>Vereeniging</city>
        <state>Gauteng</state>
        <zip>1939</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27164211778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Umhlanga Oncolgy Center ( Site 2311)</name>
      <address>
        <city>Umhlanga</city>
        <state>Kwazulu-Natal</state>
        <zip>4320</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27315663332</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cape Town Oncology Trials Pty Ltd ( Site 2312)</name>
      <address>
        <city>Kraaifontein</city>
        <state>Western Cape</state>
        <zip>7570</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27219443830</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitari Vall d Hebron ( Site 1100)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal ( Site 1101)</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913368263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre ( Site 1102)</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913908349</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel ( Site 2104)</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4021</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41612655074</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve HUG ( Site 2106)</name>
      <address>
        <city>Geneva</city>
        <state>Geneve</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41223729881</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden ( Site 2103)</name>
      <address>
        <city>Chur</city>
        <state>Grisons</state>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41812566646</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen ( Site 2102)</name>
      <address>
        <city>St. Gallen</city>
        <state>Sankt Gallen</state>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41714941067</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Zuerich ( Site 2100)</name>
      <address>
        <city>Zuerich</city>
        <state>Zurich</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+410442552154</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital ( Site 1203)</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88677317123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 1202)</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886623535355401</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 1200)</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88622312345667511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital ( Site 1204)</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8862287121212340</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospital NHS Foundation Trust ( Site 1308)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442032195250</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Trust ( Site 1306)</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441223216555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital ( Site 1301)</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441752432334</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Hong Kong</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 27, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2018</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD1, PD-1)</keyword>
  <keyword>Programmed Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

